

Product Data Sheet

Product Name: Modakafusp alfa

Cat. No.: GC74581

Chemical Properties

Cas. No. 2254522-19-3

Formula M.Wt

Solubility Storage

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Modakafusp alfa

Background

Modakafusp alfa (TAK-573) is a humanized, anti-CD38 IgG4 monoclonal antibody fused to 2 attenuated IFN α 2b molecules, which delivers interferon-alpha to CD38-expressing cells. Modakafusp alfa has direct anti-proliferative activity on multiple myeloma (MM) cancer cells in vitro and induces robust and durable antitumor responses in MM xenograft tumor models. Modakafusp alfa in combination with anti-PD-1 antibodies induces immunomodulation and antitumor responses with

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

good tolerance in mice.

References:

[1]. Dan T. Vogl MD, et al. TAK-573, an Anti-CD38/Attenuated Ifn α Fusion Protein, Has Clinical Activity and Modulates the Ifn α Receptor (IFNAR) Pathway in Patients with Relapsed/Refractory Multiple Myeloma. *Blood*. 2020, 136 (1), 37-38. [2]. Fatholahi M, et al. TAK-573, an anti-CD38-targeted attenuated interferon alpha (IFN α) fusion protein, showed anti-myeloma tumor responses in combination with standard of care (SOC) agents in multiple myeloma (MM) xenograft tumor models in vivo[J]. *Clinical Lymphoma, Myeloma and Leukemia*, 2019, 19(10): e116. [3]. Hara T, et al. A murine reactive version of TAK-573 (anti-CD38 attenuated IFN α fusion protein) shows immunomodulatory and antitumor activity, alone and in combination with standard-of-care agents, in IFN α -insensitive, immunocompetent murine multiple myeloma tumor models[J]. *Cancer Research*, 2020, 80(16_Supplement): 5546-5546. [4]. Bruins W S C, et al. Modakafusp alfa (TAK-573), a novel CD38-targeting attenuated interferon-alpha immunocytokine, kills MM cells via NK cell activation[J]. *Blood*, 2022, 140(Supplement 1): 4236-4237.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA